By Adriano Marchese
Regeneron Pharmaceuticals signed a new manufacturing-and-supply agreement with Fujifilm Diosynth Biotechnologies to double its large-scale manufacturing in the U.S.
Regeneron's new investment with Fujifilm, whose total value is estimated to exceed $3 billion, will expand the Tarrytown, N.Y., biotechnology company's manufacturing capabilities at Fujifilm's Holly Springs, N.C., campus, nearly doubling its large-scale capacity in the U.S.
This expansion will increase the production of bulk drug substances and Regeneron's commercial biologic medicines, the company said Tuesday.
Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm, which develops manufacturing for biologics, vaccines and advanced therapies, will provide Regeneron with access to its new state-of-the-art biopharmaceutical facility over a 10-year period.
The investment comes at the same time as Regeneron's initiatives in New York State, including a roughly $3.6 billion expansion of its Tarrytown campus that will bolster research, preclinical manufacturing and support facilities.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 22, 2025 06:54 ET (10:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.